X0306 4 2019-05-24 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001743881 BridgeBio Pharma, Inc. C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 0 0 1 0 Common Stock 2019-05-24 4 P 0 1103848 25.93 A 23693148 D On May 17, 2019, BridgeBio Pharma, LLC (the "Original Reporting Person") formed BridgeBio Pharma, Inc., a Delaware corporation (the "Reporting Person"). Prior to the completion of the Reporting Person's initial public offering, the Original Reporting Person intends to complete a series of transactions pursuant to which it will form BridgeBio Pharma Merger Sub LLC ("Merger Sub LLC"), an entity that will be a wholly-owned subsidiary of the Reporting Person. Merger Sub LLC will be merged with and into the Original Reporting Person prior to the completion of the Reporting Person's initial public offering, with the Original Reporting Person being the surviving entity as a wholly-owned subsidiary of the Reporting Person. As part of this merger, the unitholders of the Original Reporting Person will exchange their units in the Original Reporting Person for shares of common stock of the Reporting Person. BridgeBio Pharma, Inc. By: /s/ Neil Kumar, Name: Neil Kumar, Title: Chief Executive Officer 2019-05-29